Novai, a British biotechnology start-up, is revolutionizing clinical trial outcomes for Age-related Macular Degeneration (AMD) and glaucoma with its proprietary DARC Technology. Using a patented biologic and state-of-the-art AI algorithm, Novai aims to stratify patients based on their disease activity, which allows it to identify non-responders and avoid costly and ineffective medical management. Approved by the FDA and MHRA as an exploratory biomarker, Novai is poised to disrupt the biotech industry with its innovative approach to clinical trials.
Exploring DARC Technology
DARC Technology, or Detecting Apoptotic Retinal Cells, uses conventional imaging equipment to identify cellular-level disease activity. By measuring the impact of current and future therapeutics and interventions, Novai can provide valuable insights into disease activity and patient response. DARC Technology can also help identify non-responders, enabling more targeted and effective interventions. With the potential to expand into other indications such as Multiple Sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Diabetes Mellitus, and Cancer, Novai’s DARC technology has vast market potential.
Improving Clinical Trial Outcomes
Currently, clinical trials are expensive and time-consuming, with high rates of attrition due to low patient enrolment, ineffective interventions, or a lack of response. Novai’s DARC technology can increase patient enrolment through enriched patient cohorts consisting of those at the highest risk of rapid disease progression. By improving patient outcomes, Novai seeks to support the management of age-related conditions such as AMD, Glaucoma, and other areas of unmet medical need.
Well-funded and Poised for Growth
Novai was developed by Professor M Francesca Cordeiro at University College London through Wellcome Trust funding. The company has since raised an additional £1.1m in seed round funding led by Hoxton Ventures and Wellcome Trust. The funding will support further development of the DARC technology platform and accelerate the company’s growth plans. Novai’s progress is further reflected in various awards, including the InnovateUK Smart Grant, London Business Award 2019, and the UKBAA Angel Investment Awards 2018.
Novai is poised to disrupt the biotech industry with its DARC technology, which enhances clinical trial outcomes, improves patient enrolment, and reduces overall cost. Novai is committed to advancing the development of DARC technology across a range of disease indications and supporting the management of age-related diseases. With its well-funded and award-winning team, Novai is a company to watch as it continues to make strides in the biotech industry.
Want to supercharge your brand’s visibility within the UK tech industry? Reach startup founders, investors, and C-level executives with sponsored articles on UKT.news. Connect with us and discover how our advertising solutions can propel your brand to new heights. Explore our Sponsored Articles & Partnerships Program here.